TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00984009

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colchicine
Description: A single dose of 0.6 mg colchicine administered alone at 7:15 a.m. on Day 1

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Grapefruit Juice
Description: 240 mL of grapefruit juice ingested twice daily at 7:15 a.m. and 7:15 p.m. on Days 15 to 18.
Study: NCT01638013

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peficitinib
Description: Oral Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peficitinib
Description: Oral Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peficitinib
Description: Oral Tablet
Study: NCT00583752

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adenovirus/PSA Vaccine
Description: 1x10E8pfu in Gelfoam subcutaneously on day 0, 30, 60

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adenovirus/PSA Vaccine
Description: 1x10E8pfu in Gelfoam subcutaneously on day 0, 30, 60
Study: NCT01794208

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Follitropin Epsilon

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Follitropin Epsilon
Study: NCT00984009

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colchicine
Description: A single dose of 0.6 mg colchicine administered with grapefruit juice at 7:15 a.m. on Day 18 after an overnight fast of at least 10 hours.
Study: NCT01308853

Intervention type: DEVICE
Group type: OTHER
Intervention: Macrolane
Description: Device: Macrolane Treatment: Initial injection (incl touch-up) of a maximum of 120 ml/breast.
Study: NCT01872988

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administer Placebo to HCC patients who are indicated for TACE after randomization
Study: NCT02301052

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leek topical cream
Description: Leek (Allium Ampeloprasum Spp.Iranicum) topical cream 2 cc twice daily for 3 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo topical cream
Description: placebo topical cream 2 cc twice daily for 3 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anti-hemorrhoid topical cream
Description: Anti hemorrhoid topical cream 2 cc twice daily for 3 weeks(This cream consists of lidocaine (5% w/w), hydrocortisone acetate (7.5% w/w), aluminium sub-acetate (3.5% w/w), and zinc oxide (18% w/w). 30 g )
Study: NCT00349440

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclosporine, Refresh Plus
Description: Cyclosporine 0.4ml (in the eye) on for 3 months instill one drop in randomized eye twice daily.~Refresh Plus 0.4ml (in the eye) on for 3 months instill one drop in randomized eye twice daily.
Study: NCT06143709

Intervention type: OTHER
Intervention: DNA sample collection
Description: Patients will be asked to provide a blood or mouth wash sample for DNA extraction
Study: NCT00349440

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cyclosporine, Refresh Plus
Description: Cyclosporine 0.4ml (in the eye) on for 3 months instill one drop in randomized eye twice daily.~Refresh Plus 0.4ml (in the eye) on for 3 months instill one drop in randomized eye twice daily.
Study: NCT03063567

Intervention type: DEVICE
Group type: OTHER
Intervention: CPAP interfaces
Description: All patients in study underwent crossover prospective trial of the same 3 types of CPAP interfaces (nasal mask, oronasal mask, nasal pillows) in randomized order. Trial was 1 month duration for each interface.

Intervention type: DEVICE
Group type: OTHER
Intervention: CPAP interfaces
Description: All patients in study underwent crossover prospective trial of the same 3 types of CPAP interfaces (nasal mask, oronasal mask, nasal pillows) in randomized order. Trial was 1 month duration for each interface.
Study: NCT02923206

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TheraSorb sFlt-1 adsorber
Description: Removal of excessive sFlt-1 from the plasma of subjects/ patients with therapeutic apheresis.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TheraSorb sFlt-1 adsorber
Description: Removal of excessive sFlt-1 from the plasma of subjects/ patients with therapeutic apheresis.
Study: NCT03063567

Intervention type: DEVICE
Group type: OTHER
Intervention: CPAP interfaces
Description: All patients in study underwent crossover prospective trial of the same 3 types of CPAP interfaces (nasal mask, oronasal mask, nasal pillows) in randomized order. Trial was 1 month duration for each interface.
Study: NCT03974945

Intervention type: DEVICE
Intervention: Passive-elastic prosthetic foot
Description: The investigators will measure the biomechanics (motion, forces, and muscle activity) and metabolic rates while subjects walk using their own passive-elastic prosthesis with and without visual feedback of peak propulsive force targets.

Intervention type: DEVICE
Intervention: Powered ankle-foot prosthesis
Description: The investigators will measure the biomechanics (motion, forces, and muscle activity) and metabolic rates while subjects walk using a battery-powered ankle-foot prosthesis with and without visual feedback of peak propulsive force targets.
Study: NCT05084768

Intervention type: DIAGNOSTIC_TEST
Intervention: Donor-derived cell-free DNA
Description: As mentioned previously

Intervention type: DIAGNOSTIC_TEST
Intervention: Donor-derived cell-free DNA
Description: As mentioned previously
Study: NCT02565576

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Study: NCT02603094

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: clear fluid ingestion
Description: drinking of clear fluid in preoperative period

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: clear fluid ingestion
Description: drinking of clear fluid in preoperative period
Study: NCT02165774

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Turning OFF the neuromodulator
Description: Turning OFF the neuromodulator in 50% of the patients in a randomized way by an investigator not involved in the assessment of the clinical outcome during the regular outpatient visit 2 months after neuromodulator implantation. It then follows a 2 months double-blind phase. Thereafter, i.e. during the regular outpatient visit 4 months after neuromodulator implantation, the unblinding takes place and in patients with sacral neuromodulation OFF, the neuromodulator is switched ON.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Turning ON the neuromodulator
Study: NCT02151591

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varenicline
Description: 12-weeks of treatment. Dose will be titrated as follows:~Days 1-3: 1 0.5mg tablet once per day Days 4-7: 1 0.5mg tablet twice per day Day 8 - Week 11: 1 1mg tablet twice per day

Intervention type: DRUG
Group type: OTHER
Intervention: Varenicline
Description: 12-weeks of treatment. Dose will be titrated as follows:~Days 1-3: 1 0.5mg tablet once per day Days 4-7: 1 0.5mg tablet twice per day Day 8 - Week 11: 1 1mg tablet twice per day
Study: NCT02565576

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CFZ533
Study: NCT04440085

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midodrine Hydrochloride
Description: All patients become standard care resuscitation treatment using liquids and vasoactive drugs in order to get a median arterial pressure ≥ 65 mmHg. Midodrine will be administered according to the evolution of the patient's mean pressure.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: All patients become standard care resuscitation treatment using liquids and vasoactive drugs in order to get a median arterial pressure ≥ 65 mmHg. Placebo will be administered according to the evolution of the patient's mean pressure.
Study: NCT01755260

Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: Jejunostomy tube feeding
Description: The patients at this arm receive the nutritional support through the feeding jejunostomy tube; they can only eat or sip water through mouth
Study: NCT02923206

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TheraSorb sFlt-1 adsorber
Description: Removal of excessive sFlt-1 from the plasma of subjects/ patients with therapeutic apheresis.
Study: NCT01705886

Intervention type: PROCEDURE
Intervention: Total Knee Arthroplasty
Description: Patients undergoing manual (no robot used) surgery to replace of all 3 compartments of the knee

Intervention type: PROCEDURE
Intervention: MAKO® Robot Assisted Medial Knee Arthroplasty
Description: Patients undergoing a MAKO® robot assisted surgery to replace the medial compartment of the knee
Study: NCT01794208

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Follitropin Epsilon

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Follitropin Alfa
Study: NCT02428751

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated liposomal doxorubicin
Description: 30 mg/m2, IV (in the vein) on day 1 of each 21 day cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin
Description: 50 mg/m2, IV (in the vein) on day 1 of each 21 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375 mg/m2, IV (in the vein) on day 0 of each 21 day cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: 375 mg/m2, IV (in the vein) on day 0 of each 21 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophophamide
Description: 750 mg/m2, IV (in the vein) on day 1 of each 21 day cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophophamide
Description: 750 mg/m2, IV (in the vein) on day 1 of each 21 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: 1.4 mg/m2 (2mg in maxium), IV (in the vein) on day 1 of each 21 day cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vincristine
Description: 1.4 mg/m2 (2mg in maxium), IV (in the vein) on day 1 of each 21 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: 100mg/d, PO on day 1-5 of each 21 day cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: 100mg/d, PO on day 1-5 of each 21 day cycle
Study: NCT03990623

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Computed Tomography Perfusion Imaging
Description: Undergo perfusion CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Liver Biopsy
Description: Undergo liver biopsy
Study: NCT04208386

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-73763989
Description: JNJ-73763989 will be administered SC under fasted condition.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-73763989
Description: JNJ-73763989 will be administered SC under fasted condition.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-73763989
Description: JNJ-73763989 will be administered SC under fasted condition.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-73763989
Description: JNJ-73763989 will be administered SC under fasted condition.
Study: NCT03755674

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CHRONOTYPE-ADJUSTED DIET
Description: Those patients followed a daily caloric distribution attending to their chronotype. In this regards, 'morning' subjects ate a higher quantity of calories at the first part of the day, while 'evening' subjects ate a higher amount of calories at the second half of the day.
Study: NCT02458131

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TEEN HEED
Description: Peer-led workshops will cover behavioral skills including goal setting, self-monitoring, problem solving, contingency management, coping skills, and social support.
Study: NCT00526656

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sunitinib malate
Description: 50mg PO daily 4 weeks on -2 weeks off
Study: NCT01311115

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group commitment contract
Description: 1. Each participant is required to deposit at least 50 baht at enrollment. A deposit collector visits each participant on a weekly basis and collects additional deposits on a voluntary basis. All deposits are returned only if the smoker quits successfully within three months.~2. The project gives a matching contribution of 150 baht for the initial deposit of at least 50 baht. All participants in the treatment group are further randomized to a one-month group and a three-month group. The one-month group receives an additional 150 baht of project funds if they deposit 100 baht of their money within one month of enrollment. The three-month group receives 150 baht for depositing 100 baht within three months of enrollment.~3. Each participant is paired with another study participant. If both quit, each receives a cash bonus of 1,200 baht. At enrollment, pairs receive brief counseling on ways to support each other during the quit attempt.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Smoking cessation education and counseling
Description: Participants receive educational pamphlets on reasons to quit smoking and strategies for quitting smoking. They also receive one-time, group counseling on quitting smoking from a nurse trained in smoking cessation counseling.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smoking cessation education and counseling
Description: Participants receive educational pamphlets on reasons to quit smoking and strategies for quitting smoking. They also receive one-time, group counseling on quitting smoking from a nurse trained in smoking cessation counseling.
Study: NCT04091581

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Systane Complete
Description: Systane Complete will be instilled and rate of evaporation assessed before and after.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Systane Complete
Description: Systane Complete will be instilled and rate of evaporation assessed before and after.
Study: NCT03300024

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Expanded polytetrafluoroethylene Graft
Description: Group will receive any standard ePTFE graft (control) based on the surgeons' discretion. The graft will be placed either in the arm (brachial artery to axillary vein) or forearm (brachial artery to cephalic or suitably sized vein) depending on which location works best in your particular case.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bovine Carotid Artery Graft
Description: Group will receive the BCA graft (experimental).The graft will be placed either in the arm (brachial artery to axillary vein) or forearm (brachial artery to cephalic or suitably sized vein) depending on which location works best in your particular case.
Study: NCT03493451

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Administered intravenously
Study: NCT03424993

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary Sodium Restriction
Description: A registered dietician will counsel participants to reduce daily habitual dietary salt intake below 2000mg over 4 weeks

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Control
Description: Participants will consume their routine habitual dietary sodium intake \> 3400mg per day with regular pre determined check in phone calls from a registered dietician.
Study: NCT03941873

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitravatinib
Description: Administered orally as a capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitravatinib
Description: Administered orally as a capsule
Study: NCT01705886

Intervention type: DEVICE
Intervention: RESTORIS Multicompartmental Knee System
Description: The RESTORIS Multicompartmental Knee (MCK) System components are intended for single or multicompartmental knee replacement used in conjunction with the MAKO® Robotic Arm Interactive Orthopedic System (RIO®). The components can be used for medial compartment, lateral compartment, patellofemoral compartment, or bicompartmental (medial and patellofemoral compartments) knee replacement. The device is intended to be used with bone cement.

Intervention type: DEVICE
Intervention: Depuy Knee Replacement System
Description: The Depuy Knee Replacement System components are intended for use in total knee replacement. These components are intended for implantation with bone cement.

Intervention type: DEVICE
Intervention: Stryker® Knee Replacement System
Description: The Stryker® Knee Replacement System components are intended for use in total knee replacement. These components are intended for implantation with bone cement.
Study: NCT03842085

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant Humanized Bispecific Monoclonal Antibody MBS301
Description: The patients confirming to the eligibility criteria will be assigned to the 8 dose groups based on the sequence of inclusion. MBS301 will be administered intravenousely on day 1 of each 21-day cycle for each patient.The first intravenous infusion for each patient will be last for 90 minutes.It could be changed to 60 minutes for the subsequent infusions if the drug is well tolerated.
Study: NCT03941873

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitravatinib
Description: Administered orally as a capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitravatinib
Description: Administered orally as a capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Administered intravenously
Study: NCT03947281

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Almond snack
Description: The almond intervention will be roasted, unsalted almonds provided at 56 g/day for 28 days. Almonds provide approximately 350 kcals/day.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cereal-based snack
Description: The cereal-based intervention will be a prepared mix of cereal, pretzels, and bread sticks prepared at the WHNRC. It will be provided at the level of 350 kcals per day for 28 days.
Study: NCT04200794

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: musical instrumental training
Description: Learning to play a string instrument in a group setting (school class)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: sensitization to music
Description: sensitization to music via listening, theory, moderate practice on small percussive instruments and choir singing in a group setting (school class)
Study: NCT00970723

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: high blood pressure treatment
Description: over one 14 month period: strongly recommended hygiene-dietetic measurements, complete assessment with ambulatory measurement of the blood pressure in D0, 3 and 12 months, a therapeutic strategy according to the results, and control every 3 months

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: sleep apnea treatment
Description: over one 14 month period: complete assessment with night polysomnography in D0, 3 and 12 months, a therapeutic strategy according to the results, and control every 3 months

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: diabetic macular edema treatment
Description: over one 14 month period: control every 3 months, treatments by laser (focal or grid) are authorized until 9 months, treatments by injections are authorized until 6 months

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: diabetic macular edema treatment
Description: over one 14 month period: control every 3 months, treatments by laser (focal or grid) are authorized until 9 months, treatments by injections are authorized until 6 months
Study: NCT01244230

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fexofenadine/Allegra (M016455)
Description: Pharmaceutical form:dry syrup formulation to be suspended in water~Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fexofenadine/Allegra (M016455)
Description: Pharmaceutical form:dry syrup formulation to be suspended in water~Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fexofenadine/Allegra (M016455)
Description: Pharmaceutical form:dry syrup formulation to be suspended in water~Route of administration: oral
Study: NCT00039780

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BNP7787
Description: The treatment regimen administered in this study is a single IV doxe of paclitaxel (80 mg/m2) +/- Herceptin given over 1 hour and either BNP7787 (18.4 g/m2) or placebo given over 45 minutes each week. One treatment cycle = 8 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The treatment regimen administered in this study is a single IV doxe of paclitaxel (80 mg/m2) +/- Herceptin given over 1 hour and either BNP7787 (18.4 g/m2) or placebo given over 45 minutes each week. One treatment cycle = 8 weeks.
Study: NCT02550249

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Intravenous administration of nivolumab
Study: NCT04497688

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG-rhG-CSF
Description: Patients received a single dose of PEG-rhG-CSF per cycle. The chemotherapy regimen must meet the interval between two chemotherapy sessions at least 12 days.
Study: NCT01375647

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IPV
Description: Administered per protocol
Study: NCT01815242

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-Paclitaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-Paclitaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Study: NCT03357926

Intervention type: DIAGNOSTIC_TEST
Intervention: 24 hour Holter ECG Monitoring
Description: 24 hour Holter ECG Monitoring
Study: NCT00809835

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Galantamine
Description: Daily 8 mg galantamine capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Galantamine
Description: Daily 8 mg galantamine capsule

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computer Assisted Cognitive Behavioral Therapy (CBT)
Description: CBT a psychotherapeutic approach that addresses dysfunctional emotions, maladaptive behaviors and cognitive processes and contents through a number of goal-oriented, explicit systematic procedures. The name refers to behavior therapy, cognitive therapy, and to therapy based upon a combination of basic behavioral and cognitive principles and research.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computer Assisted Cognitive Behavioral Therapy (CBT)
Description: CBT a psychotherapeutic approach that addresses dysfunctional emotions, maladaptive behaviors and cognitive processes and contents through a number of goal-oriented, explicit systematic procedures. The name refers to behavior therapy, cognitive therapy, and to therapy based upon a combination of basic behavioral and cognitive principles and research.